Outcomes of Advanced Hodgkin Lymphoma after Umbilical Cord Blood Transplantation: A Eurocord and EBMT Lymphoma and Cellular Therapy & Immunobiology Working Party Study

被引：7

作者：

Paviglianiti, Annalisa ^{[1
,2
]}

Maio, Karina Tozatto ^{[1
,2
]}

Rocha, Vanderson ^{[1
,2
,3
]}

Gehlkopf, Eve ^{[4
]}

Milpied, Noel ^{[5
]}

Esquirol, Albert ^{[6
]}

Chevallier, Patrice ^{[7
]}

Blaise, Didier ^{[8
]}

Gac, Anne-Claire ^{[9
]}

Leblond, Veronique ^{[10
]}

Cahn, Jean Yves ^{[11
]}

Abecasis, Manuel ^{[12
]}

Zuckerman, Tsila ^{[13
,14
]}

Schouten, Harry ^{[15
]}

Gurman, Gunhan ^{[16
]}

Rubio, Marie Therese ^{[17
]}

Beguin, Yves ^{[18
,19
]}

Lopez Corral, Lucia ^{[20
]}

Nagler, Arnon ^{[21
]}

Snowden, John A. ^{[22
]}

Koc, Yener ^{[23
]}

Mordini, Nicola ^{[24
]}

Bonifazi, Francesca ^{[25
]}

Volt, Fernanda ^{[1
,2
]}

Kenzey, Chantal ^{[1
,2
]}

Robinson, Stephen Paul ^{[26
]}

Montoto, Silvia ^{[27
]}

Gluckman, Eliane ^{[1
,2
]}

Ruggeri, Annalisa ^{[1
,2
,28
]}

机构：

[1] Hop St Louis, Eurocord, Paris, France

[2] Ctr Sci Monaco, Monacord, Monaco, Monaco

[3] Hosp Sao Paulo, Dept Haematol, Sao Paulo, Brazil

[4] CHU Lapeyronie, Serv Hematol, Montpellier, France

[5] CHU Bordeaux, Hop Haut Leveque, Serv Hematol & Therapie Cellulaire, Pessac, France

[6] Hosp Santa Creu & Sant Pau, Jose Carreras Leukaemia Res Inst, Clin Hematol Serv, Barcelona, Spain

[7] Hop Hotel Dieu, Serv Hematol, Nantes, France

[8] Inst Paoli Calmettes, Serv Hematol & Therapie Cellulaire, Marseille, France

[9] Inst Hematol Basse Normandie, Caen, France

[10] Hop La Pitie Salpetriere, Hematol Clin, Paris, France

[11] CHU Grenoble Alpes, Hematol Clin, Grenoble, France

[12] Inst Portugues Oncol Francisco Gentil, BMT Unit, Lisbon, Portugal

[13] Rambam Med Ctr, Dept Hematol, Haifa, Israel

[14] Rambam Med Ctr, BMT, Haifa, Israel

[15] Univ Hosp Maastricht, Dept Internal Med Hematol & Oncol, Maastricht, Netherlands

[16] Ankara Univ, Dept Hematol, Adult Stem Cell Transplantat Unit, Ankara, Turkey

[17] Hopitaux Brabois, Serv Hematol & Therapie Cellulaire, Nancy, France

[18] CHU Liege, Dept Hematol, Liege, Belgium

[19] Univ Liege, Liege, Belgium

[20] Complejo Asistencial Univ Salamanca IBSAL, Hematol Dept, Ctr Invest Canc IBMCC, Salamanca, Spain

[21] Chaim Sheba Med Ctr, Dept Hematol, Tel Hashomer, Israel

[22] Sheffield Teaching Hosp NHS Trust, Dept Haematol, Sheffield, S Yorkshire, England

[23] Med Pk Hosp, Stem Cell Transplant Unit, Antalya, Turkey

[24] Az Osped S Croce & Carle, Div Hematol, Cuneo, Italy

[25] Seragnoli Univ Hosp S Orsola Malpighi, Inst Hematol, Bologna, Italy

[26] EBMT Lymphoma Working Party, Bristol Oncol Ctr, Bristol, Avon, England

[27] EBMT Lymphoma Working Party, Barts Hlth NHS Trust, St Bartholomews Hosp, Dept Haematooncol, London, England

[28] Osped Pediat Bambin Gesu, Hematol Dept, Dipartimento Oncoematol & Terapia Cellulare & Gen, Rome, Italy

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2018年 / 24卷 / 11期

关键词：

Hodgkin lymphoma; Umbilical cord blood transplantation; Adult patients; BONE-MARROW-TRANSPLANTATION; VERSUS-HOST-DISEASE; BRENTUXIMAB VEDOTIN; REDUCED-INTENSITY; ALLOGENEIC TRANSPLANTATION; HAPLOIDENTICAL TRANSPLANTATION; FRENCH SOCIETY; EUROPEAN GROUP; PD-1; BLOCKADE; SINGLE-ARM;

D O I：

10.1016/j.bbmt.2018.07.019

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Allogeneic stem cell transplantation is an alternative for patients with relapsed or refractory Hodgkin lymphoma (HL), but only limited data on unrelated umbilical cord blood transplantation (UCBT) are available. We analyzed 131 adults with HL who underwent UCBT in European Society for Blood and Marrow Transplantation centers from 2003 to 2015. Disease status at UCBT was complete remission (CR) in 59 patients (47%), and almost all patients had received a previous autologous stem cell transplantation. The 4-year progression-free survival (PFS) and overall survival (OS) were 26% (95% confidence interval [CI], 19% to 34%) and 46% (95% CI, 37% to 55%), respectively. Relapse incidence was 44% (95% CI, 36% to 54%), and nonrelapse mortality (NRM) was 31% (95% CI, 23% to 40%) at 4 years. In multivariate analysis refractory/relapsed disease status at UCBT was associated with increased relapse incidence (hazard ratio [HA], 3.14 [95% CI, 1.41 to 7.00], P = .005) and NRM (HR, 3.61 [95% CI, 1.58 to 827], P = .002) and lower PFS (HR, 3.45 [95% CI, 1.95 to 6.10], P < .001) and OS (HR, 3.10 [95% CI, 1.60 to 5.99], P= .001). Conditioning regimen with cyclophosphamide + fludarabine + 2 Gy total body irradiation (Cy+Flu+2GyTBI) was associated with decreased risk of NRM (HR, .26 [95% CI, .10 to .64], P = .004). Moreover, Cy+Flu+2GyTBI conditioning regimen was associated with a better OS (HR, .25 [95% CI, .12 to .50], P < .001) and PFS (HR, .51 [95% CI, .27 to .96], P = .04). UCBT is feasible in heavily pretreated patients with HL The reduced-intensity conditioning regimen with Cy+Flu+2GyTBI is associated with a better OS and NRM. However, outcomes are poor in patients not in CR at UCBT. (C) 2018 American Society for Blood and Marrow Transplantation.

引用

页码：2265 / 2270

页数：6

共 35 条

[1] PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].

Ansell, Stephen M. ;

Lesokhin, Alexander M. ;

Borrello, Ivan ;

Halwani, Ahmad ;

Scott, Emma C. ;

Gutierrez, Martin ;

Schuster, Stephen J. ;

Millenson, Michael M. ;

Cattry, Deepika ;

Freeman, Gordon J. ;

Rodig, Scott J. ;

Chapuy, Bjoern ;

Ligon, Azra H. ;

Zhu, Lili ;

Grosso, Joseph F. ;

Kim, Su Young ;

Timmerman, John M. ;

Shipp, Margaret A. ;

Armand, Philippe .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319

[2] Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor [J].

Bachanova, V. ;

Burns, L. J. ;

Wang, T. ;

Carreras, J. ;

Gale, R. P. ;

Wiernik, P. H. ;

Ballen, K. K. ;

Wirk, B. ;

Munker, R. ;

Rizzieri, D. A. ;

Chen, Y-B ;

Gibson, J. ;

Akpek, G. ;

Costa, L. J. ;

Kamble, R. T. ;

Aljurf, M. D. ;

Hsu, J. W. ;

Cairo, M. S. ;

Schouten, H. C. ;

Bacher, U. ;

Savani, B. N. ;

Wingard, J. R. ;

Lazarus, H. M. ;

Laport, G. G. ;

Montoto, S. ;

Maloney, D. G. ;

Smith, S. M. ;

Brunstein, C. ;

Saber, W. .

BONE MARROW TRANSPLANTATION, 2015, 50 (02) :197-203

[3] Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party [J].

Bazarbachi, Ali ;

Boumendil, Ariane ;

Finel, Herve ;

Mohty, Mohamad ;

Castagna, Luca ;

Peggs, Karl S. ;

Blaise, Didier ;

Afanasyev, Boris ;

Diez-Martin, Jose L. ;

Sierra, Jorge ;

Bloor, Adrian ;

Martinez, Carmen ;

Robinson, Stephen ;

Malladi, Ram ;

El-Cheikh, Jean ;

Corradini, Paolo ;

Montoto, Silvia ;

Dreger, Peter ;

Sureda, Anna .

BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 (01) :86-96

[4] Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience [J].

Bekoz, H. ;

Karadurmus, N. ;

Paydas, S. ;

Turker, A. ;

Toptas, T. ;

Tuglular, T. Firatli ;

Sonmez, M. ;

Gulbas, Z. ;

Tekgunduz, E. ;

Kaya, A. H. ;

Ozbalak, M. ;

Tastemir, N. ;

Kaynar, L. ;

Yildirim, R. ;

Karadogan, I. ;

Arat, M. ;

Tanrikulu, F. Pepedil ;

Ozkocaman, V. ;

Abali, H. ;

Turgut, M. ;

Yuksel, M. Kurt ;

Ozcan, M. ;

Dogu, M. H. ;

Hacioglu, S. Kabukcu ;

Barista, I. ;

Demirkaya, M. ;

Koseoglu, F. D. ;

Toprak, S. K. ;

Yilmaz, M. ;

Demirkurek, H. C. ;

Demirkol, O. ;

Ferhanoglu, B. .

ANNALS OF ONCOLOGY, 2017, 28 (10) :2496-2502

[5] Promising Progression-Free Survival for Patients Low and Intermediate Grade Lymphoid Malignancies after Nonmyeloablative Umbilical Cord Blood Transplantation [J].

Brunstein, Claudio G. ;

Cantero, Susano ;

Cao, Qing ;

Majhail, Navneet ;

McClune, Brian ;

Burns, Linda J. ;

Tornblyn, Marcie ;

Miller, Jeffrey S. ;

Blazar, Bruce R. ;

McGlave, Philip B. ;

Weisdorf, Daniel J. ;

Wagner, John E. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (02) :214-222

[6] Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative Conditioning for Relapsed or Refractory Hodgkin Lymphoma [J].

Burroughs, Lauri M. ;

O'Donnell, Paul V. ;

Sandmaier, Brenda M. ;

Storer, Barry E. ;

Luznik, Leo ;

Symons, Heather J. ;

Jones, Richard J. ;

Ambinder, Richard F. ;

Maris, Michael B. ;

Blume, Karl G. ;

Niederwieser, Dietger W. ;

Bruno, Benedetto ;

Maziarz, Richard T. ;

Pulsipher, MichaelA. ;

Petersen, Finn B. ;

Storb, Rainer ;

Fuchs, Ephraim J. ;

Maloney, David G. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (11) :1279-1287

[7]

Castagna L, 2017, BONE MARROW TRANSPL, V52, P683, DOI 10.1038/bmt.2016.348

[8] Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma [J].

Chen, Robert ;

Palmer, Joycelynne M. ;

Popplewell, Leslie ;

Shen, Jessica ;

Smith, Eileen ;

Delioukina, Maria ;

Kogut, Neil ;

Rosenthal, Joseph ;

Forman, Stephen ;

Nademanee, Auayporn .

ANNALS OF HEMATOLOGY, 2011, 90 (07) :803-808

[9] Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome [J].

Corradini, P. ;

Dodero, A. ;

Farina, L. ;

Fanin, R. ;

Patriarca, F. ;

Miceli, R. ;

Matteucci, P. ;

Bregni, M. ;

Scime, R. ;

Narni, F. ;

Pogliani, E. ;

Locasciulli, A. ;

Milani, R. ;

Carniti, C. ;

Bacigalupo, A. ;

Rambaldi, A. ;

Bonifazi, F. ;

Olivieri, A. ;

Gianni, A. M. ;

Tarella, C. .

LEUKEMIA, 2007, 21 (11) :2316-2323

[10] Allogeneic transplantation for Hodgkin's lymphoma [J].

Corradini, Paolo ;

Sarina, Barbara ;

Farina, Lucia .

BRITISH JOURNAL OF HAEMATOLOGY, 2011, 152 (03) :261-272

← 1 2 3 4 →